InvestorsHub Logo
Followers 52
Posts 3315
Boards Moderated 0
Alias Born 10/26/2013

Re: antihama post# 2087

Wednesday, 03/14/2018 10:02:20 AM

Wednesday, March 14, 2018 10:02:20 AM

Post# of 3283
Just listened to the quarterly CC for the 1st time as I play catch up from being away, and the only thing new is adding color to what news we may expect regarding pozio. In addition to WCLC, they mention ESMO in Oct as a possible venue for pozio news. At first I got real excited about that thinking that MDACC will provide their pozio data at WCLC and Spectrum will provide interim data of THEIR pozio exon 20 P2 trial at ESMO in essence packing a 1, 2 punch but later in the CC JT says they won't have any data from their trial to present this year. But ESMO is in their minds so the only other suspect is the breast cancer data. So I'm guessing this is where they will present the cohort of 32 patients getting the 24 mg dose before they switched over to the continuous 16 mg dose. I haven't bothered to check if any Hanmi studies might be ripe for presentation like the BC trial they presented in a proffered paper last year but that could be a possibility too. Lastly, regarding pozi, TR mentioned that "we expect one or more publications on poziotinib in major medical journals in 2018" so that's something to look forward too also.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SPPI News